Please assess the completion status of the following clinical trial:

Trial Title: A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented synovial sarcoma.~* Patients with metastatic disease or locally recurrent disease who have failed or refused standard treatment. The disease must be measurable by RECIST.~* Expected survival of at least 6 months.~* Weight at least 35 kg.~* ECOG performance scale 0-2.~* At least 3 weeks since major surgery, and at least 3 weeks since completing radiation therapy or chemotherapy (6 weeks for patients receiving mitomycin C).~* Resolution of toxicity from previous treatment to NCI-CTC grade 1 or less before treatment.~* Adequate bone marrow, renal and hepatic function.~* Able and willing to give valid written informed consent.~Exclusion Criteria:~* Clinically significant heart disease (NYHA Class III or IV).~* Other serious illnesses, e.g. serious infections requiring antibiotics or bleeding disorders.~* History of autoimmune disease.~* Serious intercurrent illness, requiring hospitalization.~* Patients with a second cancer diagnosis in the last five years, except for basal cell carcinoma, completely resected, or cervical carcinoma in situ (CIN), completely resected.~* Known HIV positivity.~* Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available.~* Chronic use of immunosuppressive drugs such as systemic corticosteroids.~* Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.~* Lack of availability for immunological and clinical follow-up assessments.~* Participation in any other clinical trial involving another investigational agent within 3 weeks prior to enrollment.~* Pregnancy or breast feeding.~* Refusal or inability to use effective means of contraception (all men, and women with childbearing potential).

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ipilimumab (Type: EXPERIMENTAL): Three doses of ipilimumab, 3 mg/kg, were administered by intravenous infusion at 3-week intervals. A 6-week observation period followed the final dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).